#China #Shanghai #Aphranel CaHA #Shanghai Moyom #Regenerative Aesthetic

Aphranel MagiCCrystal CaHA Filler Sets New Aesthetic Standards

On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its innovative regenerative aesthetic product, the Aphranel MagiCCrystal CaHA Filler, during an impressive ceremony at The Grand Halls in Shanghai. This event not only highlighted the company’s advancements but also marked a significant moment in the world of aesthetic medicine.

A Prestigious Launch Event

Hosted under the theme "APHRANEL Code Breaker, World Maker," the event drew high-profile attendees, including policy makers, medical experts, and industry leaders. Notable figures such as Wu Changfei and Li Wei, alongside Ren Dawei of the Shanghai Center for Biomedicine Development, were present at the launch, showcasing the importance of this product in advancing China's aesthetic industry on a global scale.

The conference featured keynote speeches from distinguished experts in plastic and aesthetic surgery, including professors and doctors from around the globe. Their insights and endorsements added credibility and excitement around the launch of the Aphranel Filler, emphasizing its position within a rapidly evolving market of regenerative materials used for aesthetic purposes.

Regulatory Achievements

The Aphranel MagiCCrystal CaHA Filler represents a groundbreaking achievement as it becomes the first injectable calcium hydroxylapatite (CaHA) microsphere-based dermal filler developed in China to receive NMPA Class III medical device certification. This certification is crucial, as it allows the product to meet stringent standards for safety and efficacy, making it suitable for the global market. Furthermore, it has gained certifications from the EU Medical Device regulatory body, aligning with international compliance standards. It is also recognized by Mexico's COFEPRIS, facilitating its availability across Asia, Europe, and Latin America simultaneously.

Innovative Design and Safety Features

The proprietary manufacturing techniques used in developing the Aphranel Filler allow for innovative control over particle size, porosity, and degradation rates. This approach enhances patient safety and offers structural integrity essential for aesthetic applications. The product's unique ACD-MT™ technology features a 'raspberry-like' microsphere morphology, contributing to its performance and integration within human tissue. The PCD-ETT™ crosslinked gel matrix further solidifies its favorable safety profile, characteristics that modern clients are increasingly aware of in their pursuit of beauty.

Endorsements and Collaborations

Chairman Lin Guangming spoke about the rigorous research and development journey that led to this moment, emphasizing the company's goal of restoring authenticity in medical aesthetic treatments. He noted that Aphranel aims to shift China's role in the industry from a mere follower to an innovator, reinforcing its status as a "Chinese Solution" for targeted anti-aging treatments.

The launch also involved a ceremonial butterfly release, symbolizing the transformative value of the product. Additionally, the company announced 68 partnerships with global medical aesthetics centers to facilitate extensive studies and physician training programs, ensuring practitioners are well-equipped to utilize this innovative solution.

Moreover, an expert roundtable further validated the underlying science and therapeutic potential of Aphranel's design. This gathering of esteemed researchers and clinicians discussed the product's relevance in achieving personalized treatment outcomes, emphasizing longevity and safety—a crucial concern for today's clientele.

A SOPHISTICATION IN AESTHETIC EXPERIENCE

The event concluded with a celebratory gala featuring an artistic performance integrating elements of jazz, classical music, ballet, and opera, reinforcing the product’s narrative of renewal and harmony in aesthetics. This East-West cultural dialogue was not just entertaining but emphasized the global potential of the Aphranel brand.

Chairman Lin closed the event with a powerful statement on how Aphranel sets new global standards in anti-aging treatments, highlighting the innovation as an illustration of how products made in China can achieve excellence in international health markets.

Conclusion

The launch of the Aphranel MagiCCrystal CaHA Filler is more than just the introduction of a new product; it represents a shift in the aesthetics landscape with the potential to redefine safety and effectiveness in cosmetic treatments. As Shanghai Moyom Biotechnology continues to innovate, the global aesthetic community watches closely, anticipating the positive impacts this groundbreaking product will undoubtedly bring.

For more information about Aphranel and its offerings, visit Moyom Biotechnology.